Transcutaneous Administration of Dengue Vaccines

Author(s):Show less -

Andreata-Santos, Robert ^[1] ; dos Santos Alves, Rubens Prince ^[1] ; Pereira, Sara Araujo ^[1] ; Pereira, Lennon Ramos ^[1] ; de Freitas, Carla Longo ^[1] ; Pereira, Samuel Santos ^[1] ; Venceslau-Carvalho, Alexia Adrianne ^[1] ; Castro-Amarante, Maria Fernanda ^[1] ; Pinho Favaro, Marianna Teixeira ^[1] ; Mathias-Santos, Camila ^[1] ; Amorim, Jaime Henrique ^[2] ; de Souza Ferreira, Luis Carlos ^[1]

Affiliation

^[1] Univ Sao Paulo, Inst Biomed Sci, Microbiol Dept, Vaccine Dev Lab, BR-05508000 Sao Paulo - Brazil

^[2] Fed Univ Western Bahia, Ctr Biol & Hlth Sci, BR-47810047 Barreiras, BA - Brazil

• Document type: Journal article
• Source: Viruses-Basel; v. 12, n. 5 MAY 2020.
• Web of Science Citations: 0

Abstract

In the present study, we evaluated the immunological responses induced by dengue vaccines under experimental conditions after delivery via a transcutaneous (TC) route. Vaccines against type 2 Dengue virus particles (DENV2 New Guinea C (NGC) strain) combined with enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) were administered to BALB/c mice in a three-dose immunization regimen via the TC route. As a control for the parenteral administration route, other mouse groups were immunized with the same vaccine formulation via the intradermic (ID) route. Our results showed that mice vaccinated either via the TC or ID routes developed similar protective immunity, as measured after lethal challenges with the DENV2 NGC strain. Notably, the vaccine delivered through the TC route induced lower serum antibody (IgG) responses with regard to ID-immunized mice, particularly after the third dose. The protective immunity elicited in TC-immunized mice was attributed to different antigen-specific antibody properties, such as epitope specificity and IgG subclass responses, and cellular immune responses, as determined by cytokine secretion profiles. Altogether, the results of the present study demonstrate the immunogenicity and protective properties of a dengue vaccine delivered through the TC route and offer perspectives for future clinical applications. (AU)

• FAPESP's process: 16/05570-8 - Use of Zika virus recombinant proteins for development of diagnostic methods and vaccines
• Grantee: Lennon Ramos Pereira
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 12/50362-3 - Vaccines for dengue fever control delivered via intradermal and transcutaneous routes
• Grantee: Luis Carlos de Souza Ferreira
• Support Opportunities: Research Grants - Research Partnership for Technological Innovation - PITE
• FAPESP's process: 16/20045-7 - Antigen discovery and development of serological diagnostic methods and vaccine approaches against the Zika Virus (ZIKV)
• Grantee: Luis Carlos de Souza Ferreira
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 14/17595-0 - New vaccine research based on recombinant proteins of dengue virus
• Grantee: Luis Carlos de Souza Ferreira
• Support Opportunities: Regular Research Grants
• FAPESP's process: 16/23560-0 - Development of uniplex and multiplex diagnostic platforms for arbovirus infection using recombinant proteins
• Grantee: Robert Andreata Santos
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 15/02352-7 - Vaccines for control of dengue: vaccine potential of the combination of the non-structural proteins in the generation of protective cell response in an experimental model
• Grantee: Rúbens Prince dos Santos Alves
• Support Opportunities: Scholarships in Brazil - Doctorate